Pharma Industry News

Pfizer Inc. said it would pay $3.6 billion to buy King Pharmaceuticals Inc. expanding the company’s portfolio of pain treatments.


Novartis AG will pay out-of-pocket costs for non-Medicare patients who use the company’s multiple sclerosis pill Gilenya when the drug, to be priced at $4,000 a month, goes on sale in the U.S. this week.

The Swiss drugmaker will pay as much as $800 monthly in co-payments for Gilenya, the first oral medicine for the condition, the company said in an e-mail. Novartis will also help patients navigate testing and monitoring recommended by U.S. regulators who approved Gilyena on Sept. 22, paying as much as $600 per patient for that expense.


Abbott will voluntarily withdraw Meridia® (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).  


FDA is updating the public regarding information previously communicated describing the risk of atypical fractures of the thigh, known as subtrochanteric and diaphyseal femur fractures, in patients who take bisphosphonates for osteoporosis. This information will be added to the Warnings and Precautions section of the labels approved to treat osteoporosis, including Fosamax, Fosamax Plus D, Actonel, Actonel with Calcium, Boniva, Atelvia, and Reclast (and their generic products).  A Medication Guide will also be required to be given to patients when they pick up their bisphosphonate prescription.

This entry was posted in Capital News. Bookmark the permalink.

Comments are closed.